Comparative Pharmacology
Head-to-head clinical analysis: DYNAPEN versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNAPEN versus VEETIDS 500.
DYNAPEN vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dynapen (dicloxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
250-500 mg orally every 6 hours for skin and soft tissue infections; up to 500 mg every 6 hours for respiratory tract infections.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria.
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <10%.
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic